CTIX shareholders have become restless and spoiled. We are so accustomed to having a virtual parade of good news that terrific PR's like the last update are shrugged off; in spite of the fact, it was full of positive developments on almost all of CTIX products.
IMO these doldrums should be used to accumulate more stock.
When the partnerships are announced we will not be at 2-3 dollars a share anymore and the opportunity available now will be lost.
You make a great point. Once CTIX finally has an "E" that calculation (P/E) can be incorporated into valuation / stock price decisions. If Daptomycin is generating over a billion dollars annually, wouldn't a market penetration of around 30% generate a ridiculously low P/E of around 1 given the current stock price? Just for that single indication for Brilacidin. 30% doesn't seem unreasonable for a superior product with dosing advantages.
News 
Market Data 
Discover 
AI
